Teva Pharmaceutical Industries Ltd Adr (TEVA)

Nov 30, 2025

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - Finviz

Nov 30, 2025

Nov 30, 2025

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - The Motley Fool

Nov 30, 2025

Nov 28, 2025

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December - Sahm

Nov 28, 2025

Nov 27, 2025

Is the Market Bullish or Bearish on Teva Pharmaceutical Industries Ltd? - Sahm

Nov 27, 2025

Nov 26, 2025

Teva stock hits 52-week high at 26.38 USD - Investing.com

Nov 26, 2025

Nov 25, 2025

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® - Sahm

Nov 25, 2025

Nov 19, 2025

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges - Sahm

Nov 19, 2025

Nov 17, 2025

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Shares: Cheap or Risky? - fostersleader.com

Nov 17, 2025

Nov 14, 2025

ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? - Finviz

Nov 14, 2025

Nov 13, 2025

Teva Pharma stock hits 52-week high at $25.96 By Investing.com - Investing.com Nigeria

Nov 13, 2025

Nov 13, 2025

Teva Pharma stock hits 52-week high at $25.96 - Investing.com

Nov 13, 2025

Nov 08, 2025

Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year? - sharewise.com

Nov 08, 2025

Nov 05, 2025

Why Teva Pharmaceutical Stock Rocked the Market Today - Finviz

Nov 05, 2025

Nov 05, 2025

Teva Fires on All Cylinders as Innovation and Pipeline Support Growth and Cost-Controls Lift Margins - Morningstar

Nov 05, 2025

Nov 05, 2025

Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook - Sahm

Nov 05, 2025

Nov 05, 2025

Earnings call transcript: Teva beats Q3 2025 forecasts, stock surges - Investing.com

Nov 05, 2025

Nov 05, 2025

Teva stock hits 52-week high at 23.07 USD - Investing.com

Nov 05, 2025

Nov 05, 2025

Teva stock hits 52-week high at 23.07 USD By Investing.com - Investing.com Philippines

Nov 05, 2025

Nov 02, 2025

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November - Sahm

Nov 02, 2025

Nov 01, 2025

Earnings call transcript: Teva’s Q2 2025 shows steady growth, stock rises - Investing.com

Nov 01, 2025

Oct 29, 2025

Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Trades & News - GuruFocus

Oct 29, 2025

Oct 28, 2025

eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 28, 2025

Oct 26, 2025

ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView

Oct 26, 2025

Oct 25, 2025

TEVA Stock Price and Chart — VIE:TEVA - TradingView

Oct 25, 2025

Oct 20, 2025

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe - Sahm

Oct 20, 2025

Oct 15, 2025

SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures - Sahm

Oct 15, 2025

Oct 13, 2025

Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 - Finviz

Oct 13, 2025

Oct 10, 2025

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder - Sahm

Oct 10, 2025

Oct 09, 2025

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Sahm

Oct 09, 2025

Oct 07, 2025

SciSparc And AutoMax Call Off Merger - Sahm

Oct 07, 2025

Oct 06, 2025

AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 06, 2025

Sep 21, 2025

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction - Ariva

Sep 21, 2025

Sep 20, 2025

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed - Ariva

Sep 20, 2025

Sep 16, 2025

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting - Sahm

Sep 16, 2025

Sep 14, 2025

Bayforest Capital Ltd Sells 3,875 Shares of Teva Pharmaceutical Industries Ltd. $TEVA - Defense World

Sep 14, 2025

Sep 09, 2025

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - Ariva

Sep 09, 2025

Sep 09, 2025

Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - inkl

Sep 09, 2025

Aug 29, 2025

Teva stock rises on launch of first generic weight loss GLP-1 drug - Investing.com Nigeria

Aug 29, 2025

Aug 28, 2025

Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN

Aug 28, 2025

Aug 28, 2025

Teva stock rises on launch of first generic weight loss GLP-1 drug By Investing.com - Investing.com South Africa

Aug 28, 2025

Aug 28, 2025

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss - Placera.se

Aug 28, 2025

Aug 21, 2025

TEVA Stock Price and Chart — TASE:TEVA - TradingView

Aug 21, 2025

Aug 18, 2025

Earnings call transcript: Teva’s Q2 2025 earnings beat fails to lift revenue - Investing.com

Aug 18, 2025